

## **JUST – EVOTEC BIOLOGICS: INSTALLATION OF CLEANROOM PODS AT J.POD TOULOUSE, FRANCE (EU)**

- ▶ ARRIVAL AND INSTALLATION OF G-CON CLEANROOM PODS ARE A KEY MILESTONE FOR THE J.POD FACILITY AT EVOTEC'S CAMPUS CURIE IN TOULOUSE, FRANCE
- ▶ JUST – EVOTEC BIOLOGICS' J.POD TECHNOLOGY OFFERS A PARADIGM SHIFT IN BIOMANUFACTURING WITH COST-EFFECTIVE AND TRULY FLEXIBLE CLINICAL AND COMMERCIAL SUPPLY SOLUTIONS

### **Hamburg, Germany, and Toulouse, France, 14 June 2023:**

Evotec SE (Frankfurt Stock Exchange: EVT, ISIN: DE0005664809; NASDAQ: EVO) today announced the successful arrival and start of installation of the cleanroom PODs at its J.POD biologics manufacturing facility located on Evotec's Campus Curie in Toulouse, France. Manufactured and delivered by G-CON, a global leader in off-site pre-fabricated cleanroom systems, the cleanroom PODs will be installed over the next few weeks. G-CON previously supplied the cleanroom PODs for the first J.POD facility at Just – Evotec Biologics' site in Redmond, WA (US) in August 2021.

The installation is an important step towards the completion of J.POD Toulouse, France (EU), the second facility of its kind and the first one on European ground. The GMP biomanufacturing facility features intensified, continuous bioprocessing operations housed inside autonomous cleanroom PODs, and will provide low cost clinical and commercial manufacturing capacity for biologics.

### **Dr Linda Zuckerman, Executive Vice President, Global Head**

**Biotherapeutics at Just – Evotec Biologics, commented:** “The installation of multiple cleanroom PODs by the G-CON team advances the construction of J.POD Toulouse, France (EU) significantly. The PODs are one of the cornerstones for our continuous manufacturing platform enabling advanced and efficient biomanufacturing processes available to our partners for the benefit of patients worldwide.”

At its Redmond, WA (US) facility, Just – Evotec Biologics has been performing process development and GMP clinical manufacturing for partners including the U.S. Department of Defense. In May, Just – Evotec Biologics announced a multi-year, long-term tech partnership with Sandoz for the immediate development and

---

**For further information, please contact the Corporate Communications Team:**

Hinnerk Rohwedder, Director of Global Corporate Communications, [hinnerk.rohwedder@evotec.eu](mailto:hinnerk.rohwedder@evotec.eu);

Gabriele Hansen, SVP Head of Global Corporate Communications, [gabriele.hansen@evotec.eu](mailto:gabriele.hansen@evotec.eu), [www.evotec.com](http://www.evotec.com)

subsequent manufacturing of multiple biosimilars using Just – Evotec Biologics’ continuous manufacturing platform.

The construction of J.POD Toulouse, France (EU) benefits from French government funding as part of the Investments for the future Programme (programme d’investissements d’avenir in French) and is also supported economically by the Occitanie Region and Toulouse Métropole.

#### *ABOUT G-CON*

*G-CON specializes in the design and construction of advanced cleanroom solutions for a wide range of industries. G-CON works closely with customers and A&Es to provide solutions that meet their specific needs, building PODular cleanrooms offsite, and providing modular and hybrid construction options. These offerings enable rapid deployment and easy configuration of cleanrooms while delivering the highest quality facilities, quickly and on time and on budget as well. For more information visit <http://www.gconbio.com>*

#### *ABOUT JUST – EVOTEC BIOLOGICS*

*Just – Evotec Biologics, wholly owned by Evotec SE, is a first-to-industry biologics platform company that leverages AI/ML technologies and world-leading molecular design, cell line development, process intensification and continuous manufacturing strategies to advance biotherapeutics from discovery through clinical stages to commercial launch. The Just – Evotec Biologics team combines deep industry experience in the fields of data, protein, process, and manufacturing sciences including automation with highly integrated and flexible capabilities to break through the scientific and economic barriers associated with the development of protein therapeutics. Our focus is to accelerate and expand access to biotherapeutics through scientific and technological innovation for our proprietary projects and on behalf of our partners. Learn more at [www.just-evotecbiologics.com](http://www.just-evotecbiologics.com).*

#### *ABOUT EVOTEC SE*

*Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this “Data-driven R&D Autobahn to Cures” for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 4,900 highly qualified people. The Company’s 17 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to [www.evotec.com](http://www.evotec.com) and follow us on Twitter [@Evotec](https://twitter.com/Evotec) and [LinkedIn](https://www.linkedin.com/company/evotec).*

#### *FORWARD-LOOKING STATEMENTS*

*This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to*

*have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.*